Neurocrine, Voyager reveal VY-AADC’s Phase I results at AAN 2019
Category: #health  By Saif Ali Bepari  Date: 2019-05-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Neurocrine, Voyager reveal VY-AADC’s Phase I results at AAN 2019

Neurocrine Biosciences Inc., along with Voyager Therapeutics Inc., has reportedly announced the Phase 1 results from the VY-AADC trial in eight patients suffering from Parkinson’s disease. Apparently, the patients participated in the open-label trial to test the evaluation of safety & efficacy of VY-AADC and further assess the posterior (from the back of head) surgical delivery approach.

Sources closely related to the development affirmed that treatment with VY-AADC improved the ON time in patients with Parkinson’s disease, without troublesome dyskinesia, by about 1.7 hours from baseline and also lowered the OFF time by around 2.2 hours at twelve months from the baseline. Sources added that exploratory analyses in four of the eight patients having low or no dyskinesia/ absence of ICD (impulse control disorder) at baseline showed better improvement in motor function – inclusive of a 3.2-hour improvement in good ON time from the baseline to 12 months.

Eiry Roberts, M.D., the Chief Medical Officer of Neurocrine Biosciences, was reported saying that the Phase 1 trial results in patients suffering from Parkinson’s provide evidence that administering VY-AADC allows the brain’s neurons to convert levodopa into dopamine and further augment motor function. Roberts added that the results also confirm previous data from a different, ongoing Phase 1 study showing increased coverage of the putamen with VY-AADC leading to rise in AADC enzyme activity, in addition to improvements in motor function & quality of life in Parkinson’s patients, who are in lesser need for any oral levodopa medication.

Parkinson’s disease, for the record, is a chronic, debilitating & progressive neurogenerative disorder which is known for affecting nearly one million people in the United States. Reports reveal that the VY-AADC infusions were well tolerated by patients, undergoing no SAEs (serious adverse events). Reportedly, the Phase 1 results demonstrate the posterior trajectory to be an additional surgical delivery route in the patients.

Source Credits: https://www.globenewswire.com/news-release/2019/05/05/1817140/0/en/Neurocrine-Biosciences-and-Voyager-Therapeutics-Announce-Phase-I-Results-for-VY-AADC-in-Patients-with-Parkinson-s-Disease-at-the-American-Academy-of-Neurology-Annual-Meeting.html

http://phoenix.corporate-ir.net/phoenix.zhtml?c=68817&p=irol-newsArticle&ID=2397126



About Author

Saif Ali Bepari

Email: [email protected]   

Saif Ali Bepari

Saif Ali Bepari currently works a content writer for Market Size Forecasters, Algosonline, and numerous other platforms. A Computer Science graduate who has a zest for writing over coding, he has previously dabbled into technical and creative writing. He now pens down...

Read More

More News By Saif Ali Bepari

Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate
Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate
By Saif Ali Bepari

Altimmune, Inc., a clinical stage biopharma company, has recently confirmed the closing of a formerly announced acquisition of Spitfire Pharma, Inc., including the strong GLP-1/Glucagon receptor co-agonist product cand...

NeurologyLive expands SAP program by partnering with Cleveland Clinic
NeurologyLive expands SAP program by partnering with Cleveland Clinic
By Saif Ali Bepari

NeurologyLive has reportedly added the Cleveland Clinic to its Strategic Alliance Partnership (SAP) program. Michael J. Hennessy Jr., President of NeurologyLive’s parent company MJH Associates Inc., said in a sta...

PlantEXT Family Secret form JV to develop medical cannabis products
PlantEXT Family Secret form JV to develop medical cannabis products
By Saif Ali Bepari

PlantEXT Ltd. and BB1 Acquisition Corp have reportedly announced a joint venture agreement between PlantEXT and Family Secret Ltd, an established, Israeli manufacturer and formulation developer of all-natural medical s...